Another string to the bow
Destiny have announced positive early results from its joint collaboration with SporeGen® on the prophylactic product – SPOR-COV® – to prevent respiratory infections. While the next steps in developed markets are eagerly awaited, its manufacturing partner in Vietnam (HURO) will be delivering the product to good manufacturing practice (GMP) standards.The announcement of positive preclinical prophylaxis results for the prevention of COVID-19 and influenza infections elevates SPOR-COV closer to a clinical-stage product in Destiny’s portfolio. SPOR-COV plays to Destiny’s strengths because, like its two lead Phase 3-ready products, it is intended to prevent infections, and builds on the group focus in developing clinical-grade spore-based microbiome products.
The recent news flow in the microbiome space has been very positive. Two microbiome competitors to M3 have now been approved by the FDA, Ferring’s Rebyota and Seres’s Vowst (like M3, an oral product). Seres raised $250m in debt and Destiny’s competitor Vedanta Biosciences also raised $106.5m in an equity fundraising to develop its product VE303. Yet we have previously noted, within the bounds of cross-trial comparisons, the superiority of M3 over Vowst and VE303.
Our fair value for Destiny Pharma plc remains at £254.7m (or 279 pence per share).
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.